{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:32:16Z","timestamp":1787765536512,"version":"build-2784847793"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JSPS KAKENHI Grant Number JP24K19695"],"award-info":[{"award-number":["JSPS KAKENHI Grant Number JP24K19695"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06090-3","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:44:33Z","timestamp":1731545073000},"page":"4953-4969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["mTOR inhibitors potentially preserve fertility in female patients with haematopoietic malignancies: a narrative review"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7045-8151","authenticated-orcid":false,"given":"Yuji","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2919-6337","authenticated-orcid":false,"given":"Tsukuru","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-7621","authenticated-orcid":false,"given":"Akiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0451-3378","authenticated-orcid":false,"given":"Mari","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-9271","authenticated-orcid":false,"given":"Akimasa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3945-6817","authenticated-orcid":false,"given":"Shunichiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0250-0856","authenticated-orcid":false,"given":"Takashi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"12","key":"6090_CR1","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.bbmt.2018.09.011","volume":"24","author":"PA Mehta","year":"2018","unstructured":"Mehta PA, Rotz SJ, Majhail NS (2018) Unique Challenges of Hematopoietic Cell Transplantation in adolescent and young adults with Hematologic Malignancies. Biol Blood Marrow Transpl 24(12):e11\u2013e19. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"6090_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"key":"6090_CR3","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1007\/s12094-024-03419-2","volume":"26","author":"D Li","year":"2024","unstructured":"Li D, Zhao YJ, Wang Q, Chu MW, Xie JK, Zhang CL (2024) Fertility preservation in hematological cancer patients. Clin Transl Oncol 26:1836\u20131843. https:\/\/doi.org\/10.1007\/s12094-024-03419-2","journal-title":"Clin Transl Oncol"},{"key":"6090_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/5584_2020_490","volume":"1288","author":"ZN Ozdemir","year":"2020","unstructured":"Ozdemir ZN, Bozdag SC (2020) Hematological malignancies and fertility. Adv Exp Med Biol 1288:103\u2013115. https:\/\/doi.org\/10.1007\/5584_2020_490","journal-title":"Adv Exp Med Biol"},{"key":"6090_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1200\/JCO.18.00420","volume":"37","author":"V Turan","year":"2019","unstructured":"Turan V, Bedoschi G, Rodriguez-Wallberg K, Sonmezer M, Pacheco FS, Oktem O, Taylor H, Oktay K (2019) Utility of Gonadotropin-releasing hormone agonists for Fertility Preservation: lack of biologic basis and the need to prioritize proven methods. J Clin Oncol 37:84\u201386. https:\/\/doi.org\/10.1200\/JCO.18.00420","journal-title":"J Clin Oncol"},{"issue":"1","key":"6090_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/uog.18934","volume":"51","author":"JC Senra","year":"2018","unstructured":"Senra JC, Roque M, Talim MCT, Reis FM, Tavares RLC (2018) Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis. Ultrasound Obstet Gynecol 51(1):77\u201386. https:\/\/doi.org\/10.1002\/uog.18934","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"8","key":"6090_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"S Faivre","year":"2006","unstructured":"Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671\u2013688. https:\/\/doi.org\/10.1038\/nrd2062","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"6090_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, Sengupta S, Kumar D, Garg M (2023) Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther 8(1):375. https:\/\/doi.org\/10.1038\/s41392-023-01608-z","journal-title":"Signal Transduct Target Ther"},{"key":"6090_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, Zhu X (2020) mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci 10:31. https:\/\/doi.org\/10.1186\/s13578-020-00396-1","journal-title":"Cell Biosci"},{"issue":"4","key":"6090_CR10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/ijms22041743","volume":"22","author":"NV Popova","year":"2021","unstructured":"Popova NV, J\u00fccker M (2021) The role of mTOR signaling as a therapeutic target in cancer. Int J Mol Sci 22(4):1743. https:\/\/doi.org\/10.3390\/ijms22041743","journal-title":"Int J Mol Sci"},{"issue":"16","key":"6090_CR11","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.3390\/molecules27165295","volume":"27","author":"B Mao","year":"2022","unstructured":"Mao B, Zhang Q, Ma L, Zhao DS, Zhao P, Yan P (2022) Overview of research into mTOR inhibitors. Molecules 27(16):5295. https:\/\/doi.org\/10.3390\/molecules27165295","journal-title":"Molecules"},{"issue":"7253","key":"6090_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","volume":"460","author":"DE Harrison","year":"2009","unstructured":"Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460(7253):392\u2013395. https:\/\/doi.org\/10.1038\/nature08221","journal-title":"Nature"},{"issue":"2","key":"6090_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/gerona\/glq178","volume":"66","author":"RA Miller","year":"2011","unstructured":"Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol Biol Sci Med Sci 66(2):191\u2013201. https:\/\/doi.org\/10.1093\/gerona\/glq178","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"24","key":"6090_CR14","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.4161\/cc.10.24.18486","volume":"10","author":"VN Anisimov","year":"2011","unstructured":"Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV (2011) Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10(24):4230\u20134236. https:\/\/doi.org\/10.4161\/cc.10.24.18486","journal-title":"Cell Cycle"},{"issue":"8","key":"6090_CR15","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1172\/JCI67674","volume":"123","author":"F Neff","year":"2013","unstructured":"Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schr\u00f6der S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Garrett L, Hans W, Hettich MM, Holtmeier R, H\u00f6lter SM, Moreth K, Prehn C, Puk O, R\u00e1cz I, Rathkolb B, Rozman J, Naton B, Ordemann R, Adamski J, Beckers J, Bekeredjian R, Busch DH, Ehninger G, Graw J, H\u00f6fler H, Klingenspor M, Klopstock T, Ollert M, Stypmann J, Wolf E, Wurst W, Zimmer A, Fuchs H, Gailus-Durner V, de Hrabe M, Ehninger D (2013) Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 123(8):3272\u20133291. https:\/\/doi.org\/10.1172\/JCI67674","journal-title":"J Clin Invest"},{"issue":"2","key":"6090_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/gerona\/glt056","volume":"69","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, Diaz V, Sloane L, Maslin K, Treaster S, R\u00e9ndon S, van Remmen H, Ward W, Javors M, Richardson A, Austad SN, Fischer K (2014) Rapamycin extends life and health in C57BL\/6 mice. J Gerontol Biol Sci Med Sci 69(2):119\u2013130. https:\/\/doi.org\/10.1093\/gerona\/glt056","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"3","key":"6090_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/acel.12194","volume":"13","author":"RA Miller","year":"2014","unstructured":"Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, Pletcher S, Salmon AB, Sharp ZD, Van Roekel S, Winkleman L, Strong R (2014) Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13(3):468\u2013477. https:\/\/doi.org\/10.1111\/acel.12194","journal-title":"Aging Cell"},{"issue":"2","key":"6090_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1124\/mol.109.056705","volume":"76","author":"DJ Waxman","year":"2009","unstructured":"Waxman DJ, Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76(2):215\u2013228. https:\/\/doi.org\/10.1124\/mol.109.056705","journal-title":"Mol Pharmacol"},{"issue":"5","key":"6090_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1474-9726.2008.00414.x","volume":"7","author":"R Strong","year":"2008","unstructured":"Strong R, Miller RA, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR, Harrison DE (2008) Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 7(5):641\u2013650. https:\/\/doi.org\/10.1111\/j.1474-9726.2008.00414.x","journal-title":"Aging Cell"},{"issue":"2","key":"6090_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/acel.12170","volume":"13","author":"DE Harrison","year":"2014","unstructured":"Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, Fernandez E, Flurkey K, Javors MA, Nadon NL, Nelson JF, Pletcher S, Simpkins JW, Smith D, Wilkinson JE, Miller RA (2014) Acarbose, 17-\u03b1-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell 13(2):273\u2013282. https:\/\/doi.org\/10.1111\/acel.12170","journal-title":"Aging Cell"},{"issue":"7","key":"6090_CR21","doi-asserted-by":"publisher","first-page":"e6186","DOI":"10.1371\/journal.pone.0006186","volume":"4","author":"K Jagarlamudi","year":"2009","unstructured":"Jagarlamudi K, Liu L, Adhikari D, Reddy P, Idahl A, Ottander U, Lundin E, Liu K (2009) Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN\/PI3K signaling in oocytes in controlling follicular activation. PLoS ONE 4(7):e6186. https:\/\/doi.org\/10.1371\/journal.pone.0006186","journal-title":"PLoS ONE"},{"issue":"5863","key":"6090_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1126\/science.1152257","volume":"319","author":"P Reddy","year":"2008","unstructured":"Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, Du C, Tang W, H\u00e4m\u00e4l\u00e4inen T, Peng SL, Lan ZJ, Cooney AJ, Huhtaniemi I, Liu K (2008) Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 319(5863):611\u2013613. https:\/\/doi.org\/10.1126\/science.1152257","journal-title":"Science"},{"issue":"5929","key":"6090_CR23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1126\/science.1171396","volume":"324","author":"HY Fan","year":"2009","unstructured":"Fan HY, Liu Z, Shimada M, Sterneck E, Johnson PF, Hedrick SM, Richards JS (2009) MAPK3\/1 (ERK1\/2) in ovarian granulosa cells are essential for female fertility. Science 324(5929):938\u2013941. https:\/\/doi.org\/10.1126\/science.1171396","journal-title":"Science"},{"issue":"185","key":"6090_CR24","doi-asserted-by":"publisher","first-page":"185ra62","DOI":"10.1126\/scitranslmed.3005402","volume":"5","author":"L Kalich-Philosoph","year":"2013","unstructured":"Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, Wolf I, Kanety H, Sredni B, Meirow D (2013) Cyclophosphamide triggers follicle activation and burnout; AS101 prevents follicle loss and preserves fertility. Sci Transl Med 5(185):185ra62. https:\/\/doi.org\/10.1126\/scitranslmed.3005402","journal-title":"Sci Transl Med"},{"issue":"12","key":"6090_CR25","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1073\/pnas.1617233114","volume":"114","author":"KN Goldman","year":"2017","unstructured":"Goldman KN, Chenette D, Arju R, Duncan FE, Keefe DL, Grifo JA, Schneider RJ (2017) mTORC1\/2 inhibition preserves ovarian function and fertility during genotoxic chemotherapy. Proc Natl Acad Sci U S A 114(12):3186\u20133191. https:\/\/doi.org\/10.1073\/pnas.1617233114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6090_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13048-017-0350-3","volume":"10","author":"L Zhou","year":"2017","unstructured":"Zhou L, Xie Y, Li S, Liang Y, Qiu Q, Lin H, Zhang Q (2017) Rapamycin prevents cyclophosphamide-induced over-activation of primordial follicle pool through PI3K\/Akt\/mTOR signaling pathway in vivo. J Ovarian Res 10(1):56. https:\/\/doi.org\/10.1186\/s13048-017-0350-3","journal-title":"J Ovarian Res"},{"issue":"4","key":"6090_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1262\/jrd.2022-001","volume":"68","author":"X Chen","year":"2022","unstructured":"Chen X, Tang Z, Guan H, Xia H, Gu C, Xu Y, Li B, Zhang W (2022) Rapamycin maintains the primordial follicle pool and protects ovarian reserve against cyclophosphamide-induced damage. J Reprod Dev 68(4):287\u2013294. https:\/\/doi.org\/10.1262\/jrd.2022-001","journal-title":"J Reprod Dev"},{"issue":"6","key":"6090_CR28","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/humrep\/dead064","volume":"38","author":"O Kashi","year":"2023","unstructured":"Kashi O, Roness H, Spector I, Derech-Haim S, Meirow D (2023) Dual suppression of follicle activation pathways completely prevents the cyclophosphamide-induced loss of ovarian reserve. Hum Reprod 38(6):1086\u20131098. https:\/\/doi.org\/10.1093\/humrep\/dead064","journal-title":"Hum Reprod"},{"issue":"2","key":"6090_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/humrep\/dead255","volume":"39","author":"R Rosario","year":"2024","unstructured":"Rosario R, Stewart HL, Spears N, Telfer EE, Anderson RA (2024) Anti-mullerian hormone attenuates both cyclophosphamide-induced damage and PI3K signalling activation, while rapamycin attenuates only PI3K signalling activation, in human ovarian cortex in vitro. Hum Reprod 39(2):382\u2013392. https:\/\/doi.org\/10.1093\/humrep\/dead255","journal-title":"Hum Reprod"},{"key":"6090_CR30","doi-asserted-by":"publisher","unstructured":"Tanaka Y, Amano T, Nakamura A, Yoshino F, Takebayashi A, Takahashi A, Yamanaka H, Inatomi A, Hanada T, Yoneoka Y, Tsuji S (2024) Rapamycin prevents cyclophosphamide-induced ovarian follicular loss and potentially inhibits tumour proliferation in a breast cancer xenograft mouse model. Hum Reprod: Deae 085. https:\/\/doi.org\/10.1093\/humrep\/deae085","DOI":"10.1093\/humrep\/deae085"},{"issue":"1","key":"6090_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.gene.2013.03.039","volume":"523","author":"XM Zhang","year":"2013","unstructured":"Zhang XM, Li L, Xu JJ, Wang N, Liu WJ, Lin XH, Fu YC, Luo LL (2013) Rapamycin preserves the follicle pool reserve and prolongs the ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression. Gene 523(1):82\u201387. https:\/\/doi.org\/10.1016\/j.gene.2013.03.039","journal-title":"Gene"},{"issue":"4","key":"6090_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/acel.12617","volume":"16","author":"X Dou","year":"2017","unstructured":"Dou X, Sun Y, Li J, Zhang J, Hao D, Liu W, Wu R, Kong F, Peng X, Li J (2017) Short-term rapamycin treatment increases ovarian lifespan in young and middle-aged female mice. Aging Cell 16(4):825\u2013836. https:\/\/doi.org\/10.1111\/acel.12617","journal-title":"Aging Cell"},{"issue":"2","key":"6090_CR33","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10616-018-0196-6","volume":"70","author":"H Yang","year":"2018","unstructured":"Yang H, Yao X, Tang F, Wei Y, Hua J, Peng S (2018) Characterization of female germline stem cells from adult mouse ovaries and the role of rapamycin on them. Cytotechnology 70(2):843\u2013854. https:\/\/doi.org\/10.1007\/s10616-018-0196-6","journal-title":"Cytotechnology"},{"key":"6090_CR34","doi-asserted-by":"publisher","first-page":"110694","DOI":"10.1016\/j.mce.2019.110694","volume":"504","author":"Y Sato","year":"2020","unstructured":"Sato Y, Kawamura K (2020) Rapamycin treatment maintains developmental potential of oocytes in mice and follicle reserve in human cortical fragments grafted into immune-deficient mice. Mol Cell Endocrinol 504:110694. https:\/\/doi.org\/10.1016\/j.mce.2019.110694","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"6090_CR35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/humrep\/dey250","volume":"33","author":"J Grosbois","year":"2018","unstructured":"Grosbois J, Demeestere I (2018) Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation. Hum Reprod 33(9):1705\u20131714. https:\/\/doi.org\/10.1093\/humrep\/dey250","journal-title":"Hum Reprod"},{"issue":"9","key":"6090_CR36","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s10815-020-01875-7","volume":"37","author":"S Celik","year":"2020","unstructured":"Celik S, Ozkavukcu S, Celik-Ozenci C (2020) Altered expression of activator proteins that control follicle reserve after ovarian tissue cryopreservation\/transplantation and primordial follicle loss prevention by rapamycin. J Assist Reprod Genet 37(9):2119\u20132136. https:\/\/doi.org\/10.1007\/s10815-020-01875-7","journal-title":"J Assist Reprod Genet"},{"issue":"1","key":"6090_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13048-021-00846-5","volume":"14","author":"C Terren","year":"2021","unstructured":"Terren C, Nisolle M, Munaut C (2021) Pharmacological inhibition of the PI3K\/PTEN\/Akt and mTOR signalling pathways limits follicle activation induced by ovarian cryopreservation and in vitro culture. J Ovarian Res 14(1):95. https:\/\/doi.org\/10.1186\/s13048-021-00846-5","journal-title":"J Ovarian Res"},{"key":"6090_CR38","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.bbrc.2020.10.110","volume":"534","author":"W Liu","year":"2021","unstructured":"Liu W, Zhang J, Wang L, Liang S, Xu B, Ying X, Li J (2021) The protective effects of rapamycin pretreatment on ovarian damage during ovarian tissue cryopreservation and transplantation. Biochem Biophys Res Commun 534:780\u2013786. https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.110","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"6090_CR39","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/medicina59081474","volume":"59","author":"J Bindels","year":"2023","unstructured":"Bindels J, Squatrito M, Bernet L, Nisolle M, Henry L, Munaut C (2023) The mTOR inhibitor rapamycin counteracts follicle Activation Induced by Ovarian Cryopreservation in Murine Transplantation models. Med (Kaunas) 59(8):1474. https:\/\/doi.org\/10.3390\/medicina59081474","journal-title":"Med (Kaunas)"},{"issue":"1","key":"6090_CR40","doi-asserted-by":"publisher","first-page":"e8772","DOI":"10.1371\/journal.pone.0008772","volume":"5","author":"WH Wallace","year":"2010","unstructured":"Wallace WH, Kelsey TW (2010) Human ovarian reserve from conception to the menopause. PLoS ONE 5(1):e8772. https:\/\/doi.org\/10.1371\/journal.pone.0008772","journal-title":"PLoS ONE"},{"issue":"6","key":"6090_CR41","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1515\/mr-2022-0031","volume":"2","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Xu W, Liu L (2022) Ovarian aging: mechanisms and intervention strategies. Med Rev 2(6):590\u2013610. https:\/\/doi.org\/10.1515\/mr-2022-0031","journal-title":"Med Rev"},{"key":"6090_CR42","doi-asserted-by":"publisher","first-page":"702446","DOI":"10.3389\/fendo.2021.702446","volume":"12","author":"K Papageorgiou","year":"2021","unstructured":"Papageorgiou K, Mastora E, Zikopoulos A, Grigoriou ME, Georgiou I, Michaelidis TM (2021) Interplay between mTOR and hippo signaling in the ovary: clinical choice guidance between different gonadotropin preparations for better IVF. Front Endocrinol (Lausanne) 12:702446. https:\/\/doi.org\/10.3389\/fendo.2021.702446","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"6090_CR43","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3390\/cells10061491","volume":"10","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Feng H, Zhang Y, Zhang JV, Wang X, Liu D, Wang T, Li RHW, Ng EHY, Yeung WSB, Rodriguez-Wallberg KA, Liu K (2021) Current understandings of core pathways for the activation of mammalian primordial follicles. Cells 10(6):1491. https:\/\/doi.org\/10.3390\/cells10061491","journal-title":"Cells"},{"issue":"4","key":"6090_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10815-015-0428-z","volume":"32","author":"ER Cardozo","year":"2015","unstructured":"Cardozo ER, Thomson AP, Karmon AE, Dickinson KA, Wright DL, Sabatini ME (2015) Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience. J Assist Reprod Genet 32(4):587\u2013596. https:\/\/doi.org\/10.1007\/s10815-015-0428-z","journal-title":"J Assist Reprod Genet"},{"issue":"2","key":"6090_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/rmb2.12263","volume":"18","author":"T Nakasuji","year":"2019","unstructured":"Nakasuji T, Kawai K, Ishikawa T, Teraoka K, Takeuchi S, Miyagawa T, Nara K, Kidera N, Harada T, Miyasaka N (2019) Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer. Reprod Med Biol 18(2):167\u2013172. https:\/\/doi.org\/10.1002\/rmb2.12263","journal-title":"Reprod Med Biol"},{"issue":"3","key":"6090_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.fertnstert.2020.07.008","volume":"114","author":"A Baerwald","year":"2020","unstructured":"Baerwald A, Pierson R (2020) Ovarian follicular waves during the menstrual cycle: physiologic insights into novel approaches for ovarian stimulation. Fertil Steril 114(3):443\u2013457. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.07.008","journal-title":"Fertil Steril"},{"issue":"1","key":"6090_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12958-023-01167-6","volume":"21","author":"B Xie","year":"2023","unstructured":"Xie B, Li J, Huang Y, Hang F, Hu Q, Yu J, Qin A (2023) Assessing the impact of transplant site on ovarian tissue transplantation: a single-arm meta-analysis. Reprod Biol Endocrinol 21(1):120. https:\/\/doi.org\/10.1186\/s12958-023-01167-6","journal-title":"Reprod Biol Endocrinol"},{"issue":"10","key":"6090_CR48","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1055\/s-0042-115017","volume":"76","author":"MW Beckmann","year":"2016","unstructured":"Beckmann MW, Dittrich R, Findeklee S, Lotz L (2016) Surgical aspects of ovarian tissue removal and ovarian tissue transplantation for Fertility Preservation. Geburtshilfe Frauenheilkd 76(10):1057\u20131064. https:\/\/doi.org\/10.1055\/s-0042-115017","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"12","key":"6090_CR49","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","volume":"31","author":"M Lambertini","year":"2020","unstructured":"Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, Paluch-Shimon S, Halaska MJ, Uzan C, Meissner J, von Wolff M, Anderson RA, Jordan K (2020) Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines\u2020. Ann Oncol 31(12):1664\u20131678. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.006","journal-title":"Ann Oncol"},{"issue":"19","key":"6090_CR50","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, Wallace WH, Wang ET, Loren AW (2018) Fertility preservation in patients with Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 36(19):1994\u20132001. https:\/\/doi.org\/10.1200\/JCO.2018.78.1914","journal-title":"J Clin Oncol"},{"issue":"4","key":"6090_CR51","doi-asserted-by":"publisher","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","volume":"2020","author":"RA Anderson","year":"2020","unstructured":"Anderson RA, Amant F, Braat D, D\u2019Angelo A, Chuva de Sousa Lopes SM, Demeestere I, Dwek S, Frith L, Lambertini M, Maslin C, Moura-Ramos M, Nogueira D, Rodriguez-Wallberg K, Vermeulen N (2020) ESHRE guideline: female fertility preservation. Hum Reprod Open 2020(4):hoaa052. https:\/\/doi.org\/10.1093\/hropen\/hoaa052","journal-title":"Hum Reprod Open"},{"issue":"5","key":"6090_CR52","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.fertnstert.2021.03.008","volume":"115","author":"MM Dolmans","year":"2021","unstructured":"Dolmans MM, von Wolff M, Poirot C, Diaz-Garcia C, Cacciottola L, Boissel N, Liebenthron J, Pellicer A, Donnez J, Andersen CY (2021) Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertil Steril 115(5):1102\u20131115. https:\/\/doi.org\/10.1016\/j.fertnstert.2021.03.008","journal-title":"Fertil Steril"},{"issue":"4","key":"6090_CR53","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10815-018-1144-2","volume":"35","author":"SE Gellert","year":"2018","unstructured":"Gellert SE, Pors SE, Kristensen SG, Bay-Bj\u00f8rn AM, Ernst E, Yding Andersen C (2018) Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet 35(4):561\u2013570. https:\/\/doi.org\/10.1007\/s10815-018-1144-2","journal-title":"J Assist Reprod Genet"},{"issue":"22","key":"6090_CR54","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1182\/blood-2012-01-403022","volume":"120","author":"T Greve","year":"2012","unstructured":"Greve T, Clasen-Linde E, Andersen MT, Andersen MK, S\u00f8rensen SD, Rosendahl M, Ralfkiaer E, Andersen CY (2012) Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells. Blood 120(22):4311\u20134316. https:\/\/doi.org\/10.1182\/blood-2012-01-403022","journal-title":"Blood"},{"issue":"6","key":"6090_CR55","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.fertnstert.2013.03.027","volume":"99","author":"MM Dolmans","year":"2013","unstructured":"Dolmans MM, Luyckx V, Donnez J, Andersen CY, Greve T (2013) Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril 99(6):1514\u20131522. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.03.027","journal-title":"Fertil Steril"},{"issue":"2","key":"6090_CR56","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.fertnstert.2010.07.1068","volume":"95","author":"SE Bittinger","year":"2011","unstructured":"Bittinger SE, Nazaretian SP, Gook DA, Parmar C, Harrup RA, Stern CJ (2011) Detection of Hodgkin lymphoma within ovarian tissue. Fertil Steril 95(2):803. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.07.1068..e3-6","journal-title":"Fertil Steril"},{"issue":"5","key":"6090_CR57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/humupd\/dmt020","volume":"19","author":"L Bastings","year":"2013","unstructured":"Bastings L, Beerendonk CC, Westphal JR, Massuger LF, Kaal SE, van Leeuwen FE, Braat DD, Peek R (2013) Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update 19(5):483\u2013506. https:\/\/doi.org\/10.1093\/humupd\/dmt020","journal-title":"Hum Reprod Update"},{"issue":"1","key":"6090_CR58","doi-asserted-by":"publisher","first-page":"hox001","DOI":"10.1093\/hropen\/hox001","volume":"2017","author":"RA Anderson","year":"2017","unstructured":"Anderson RA, Wallace WHB, Telfer EE (2017) Ovarian tissue cryopreservation for fertility preservation: clinical and research perspectives. Hum Reprod Open 2017(1):hox001. https:\/\/doi.org\/10.1093\/hropen\/hox001","journal-title":"Hum Reprod Open"},{"issue":"3","key":"6090_CR59","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.rbmo.2012.12.001","volume":"26","author":"KT Schmidt","year":"2013","unstructured":"Schmidt KT, Nyboe Andersen A, Greve T, Ernst E, Loft A, Yding Andersen C (2013) Fertility in cancer patients after cryopreservation of one ovary. Reprod Biomed Online 26(3):272\u2013279. https:\/\/doi.org\/10.1016\/j.rbmo.2012.12.001","journal-title":"Reprod Biomed Online"},{"issue":"5","key":"6090_CR60","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/jrr\/rrab066","volume":"62","author":"K Akahane","year":"2021","unstructured":"Akahane K, Shirai K, Wakatsuki M, Suzuki M, Hatanaka S, Takahashi Y, Kawahara M, Ogawa K, Takahashi S, Oyama-Manabe N, Ashizawa M, Kimura SI, Kako S, Kanda Y (2021) Dosimetric evaluation of ovaries and pelvic bones associated with clinical outcomes in patients receiving total body irradiation with ovarian shielding. J Radiat Res 62(5):918\u2013925. https:\/\/doi.org\/10.1093\/jrr\/rrab066","journal-title":"J Radiat Res"},{"issue":"8","key":"6090_CR61","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.ejso.2019.02.017","volume":"45","author":"EJ Hoekman","year":"2019","unstructured":"Hoekman EJ, Broeders EABJ, Louwe LA, Nout RA, Jansen FW, de Kroon CD (2019) Ovarian function after ovarian transposition and additional pelvic radiotherapy: a systematic review. Eur J Surg Oncol 45(8):1328\u20131340. https:\/\/doi.org\/10.1016\/j.ejso.2019.02.017","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"6090_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.fertnstert.2012.04.021","volume":"98","author":"B Lawrenz","year":"2012","unstructured":"Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, Henes M (2012) Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-hodgkin-lymphoma\u2013evaluation by using antim\u00fcllerian hormone and retrieved oocytes. Fertil Steril 98(1):141\u2013144. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.04.021","journal-title":"Fertil Steril"},{"issue":"3","key":"6090_CR63","doi-asserted-by":"publisher","first-page":"hoad024","DOI":"10.1093\/hropen\/hoad024","volume":"2023","author":"M Wu","year":"2023","unstructured":"Wu M, Zhu Q, Huang Y, Tang W, Dai J, Guo Y, Xiong J, Zhang J, Zhou S, Fu F, Wu M, Wang S (2023) Ovarian reserve in reproductive-aged patients with cancer before gonadotoxic treatment: a systematic review and meta-analysis. Hum Reprod Open 2023(3):hoad024. https:\/\/doi.org\/10.1093\/hropen\/hoad024","journal-title":"Hum Reprod Open"},{"issue":"5","key":"6090_CR64","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10815-016-0689-1","volume":"33","author":"J Lekovich","year":"2016","unstructured":"Lekovich J, Lobel ALS, Stewart JD, Pereira N, Kligman I, Rosenwaks Z (2016) Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. J Assist Reprod Genet 33(5):657\u2013662. https:\/\/doi.org\/10.1007\/s10815-016-0689-1","journal-title":"J Assist Reprod Genet"},{"issue":"2","key":"6090_CR65","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/humrep\/det442","volume":"29","author":"W van Dorp","year":"2014","unstructured":"van Dorp W, van den Heuvel-Eibrink MM, de Vries AC, Pluijm SM, Visser JA, Pieters R, Laven JS (2014) Decreased serum anti-M\u00fcllerian hormone levels in girls with newly diagnosed cancer. Hum Reprod 29(2):337\u2013342. https:\/\/doi.org\/10.1093\/humrep\/det442","journal-title":"Hum Reprod"},{"issue":"5","key":"6090_CR66","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.fertnstert.2016.06.035","volume":"106","author":"R Paradisi","year":"2016","unstructured":"Paradisi R, Vicenti R, Macciocca M, Seracchioli R, Rossi S, Fabbri R (2016) High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-hodgkin lymphoma. Fertil Steril 106(5):1176\u20131182. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.06.035","journal-title":"Fertil Steril"},{"issue":"1","key":"6090_CR67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/life14010035","volume":"14","author":"M Plotogea","year":"2023","unstructured":"Plotogea M, Zgura A, Mehedin\u021bu C, Scurtu F, Petca A, Varlas VN, Bors RG, Edu A, Ionescu OM, Andreescu M, Mateescu RN, Isam AJ (2023) Women\u2019s sexual dysfunctions following stem cell transplant and the impact on couple relationship. Life (Basel) 14(1):35. https:\/\/doi.org\/10.3390\/life14010035","journal-title":"Life (Basel)"},{"issue":"3","key":"6090_CR68","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1200\/JCO.2011.37.1989","volume":"30","author":"MA van der Kaaij","year":"2012","unstructured":"van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Simons AH, Lugtenburg PJ, Aleman BM, Noordijk EM, Ferm\u00e9 C, Thomas J, Stamatoullas A, Fruchart C, Brice P, Gaillard I, Bologna S, Ong F, Eghbali H, Doorduijn JK, Morschhauser F, Sebban C, Roesink JM, Bouteloup M, Van Hoof A, Raemaekers JM, Henry-Amar M, Kluin-Nelemans HC (2012) Premature ovarian failure and fertility in long-term survivors of Hodgkin\u2019s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d\u2019Etude Des Lymphomes De l\u2019Adulte Cohort Study. J Clin Oncol 30(3):291\u2013299. https:\/\/doi.org\/10.1200\/JCO.2011.37.1989","journal-title":"J Clin Oncol"},{"issue":"2","key":"6090_CR69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","volume":"31","author":"K Behringer","year":"2013","unstructured":"Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlp\u00fctz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P (2013) Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 31(2):231\u2013239. https:\/\/doi.org\/10.1200\/JCO.2012.44.3721","journal-title":"J Clin Oncol"},{"issue":"10","key":"6090_CR70","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1093\/humrep\/del201","volume":"21","author":"RA Anderson","year":"2006","unstructured":"Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583\u20132592. https:\/\/doi.org\/10.1093\/humrep\/del201","journal-title":"Hum Reprod"},{"issue":"8","key":"6090_CR71","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/annonc\/mdv227","volume":"26","author":"J Meissner","year":"2015","unstructured":"Meissner J, Tichy D, Katzke V, K\u00fchn T, Dietrich S, Schmitt T, Ziepert M, Kuhnt E, Rixecker T, Zorn M, Witzens-Harig M, Pfreundschuh M, Ho AD (2015) Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Ann Oncol 26(8):1771\u20131776. https:\/\/doi.org\/10.1093\/annonc\/mdv227","journal-title":"Ann Oncol"},{"issue":"12","key":"6090_CR72","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/bmt.2015.178","volume":"50","author":"S Akhtar","year":"2015","unstructured":"Akhtar S, Youssef I, Soudy H, Elhassan TA, Rauf SM, Maghfoor I (2015) Prevalence of menstrual cycles and outcome of 50 pregnancies after high-dose chemotherapy and auto-SCT in non-hodgkin and Hodgkin lymphoma patients younger than 40 years. Bone Marrow Transpl 50(12):1551\u20131556. https:\/\/doi.org\/10.1038\/bmt.2015.178","journal-title":"Bone Marrow Transpl"},{"issue":"23","key":"6090_CR73","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1200\/JCO.2007.10.8993","volume":"25","author":"C Hammond","year":"2007","unstructured":"Hammond C, Abrams JR, Syrjala KL (2007) Fertility and risk factors for elevated infertility concern in 10-year hematopoietic cell transplant survivors and case-matched controls. J Clin Oncol 25(23):3511\u20133517. https:\/\/doi.org\/10.1200\/JCO.2007.10.8993","journal-title":"J Clin Oncol"},{"issue":"7","key":"6090_CR74","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/humrep\/deg295","volume":"18","author":"L Tauchmanov\u00e0","year":"2003","unstructured":"Tauchmanov\u00e0 L, Selleri C, De Rosa G, Esposito M, Orio F, Palomba S, Bifulco G, Nappi C, Lombardi G, Rotoli B, Colao A (2003) Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. Hum Reprod 18(7):1410\u20131416. https:\/\/doi.org\/10.1093\/humrep\/deg295","journal-title":"Hum Reprod"},{"issue":"3","key":"6090_CR75","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1182\/blood-2006-01-0176","volume":"108","author":"A Rov\u00f3","year":"2006","unstructured":"Rov\u00f3 A, Tichelli A, Passweg JR, Heim D, Meyer-Monard S, Holzgreve W, Gratwohl A, De Geyter C (2006) Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood 108(3):1100\u20131105. https:\/\/doi.org\/10.1182\/blood-2006-01-0176","journal-title":"Blood"},{"issue":"9","key":"6090_CR76","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1182\/blood-2016-07-728337","volume":"129","author":"S Shimoji","year":"2017","unstructured":"Shimoji S, Hashimoto D, Tsujigiwa H, Miyawaki K, Kato K, Takahashi S, Ogasawara R, Jiromaru T, Iwasaki H, Miyamoto T, Akashi K, Teshima T (2017) Graft-versus-host disease targets ovary and causes female infertility in mice. Blood 129(9):1216\u20131225. https:\/\/doi.org\/10.1182\/blood-2016-07-728337","journal-title":"Blood"},{"issue":"10","key":"6090_CR77","first-page":"1163","volume":"88","author":"S Spinelli","year":"2003","unstructured":"Spinelli S, Chiodi S, Costantini S, Van Lint MT, Raiola AM, Ravera GB, Bacigalupo A (2003) Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 88(10):1163\u20131168","journal-title":"Haematologica"},{"issue":"6","key":"6090_CR78","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/bmt.2016.315","volume":"52","author":"BK Hamilton","year":"2017","unstructured":"Hamilton BK, Goje O, Savani BN, Majhail NS, Stratton P (2017) Clinical management of genital chronic GvHD. Bone Marrow Transpl 52(6):803\u2013810. https:\/\/doi.org\/10.1038\/bmt.2016.315","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"6090_CR79","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.bbmt.2003.08.001","volume":"9","author":"LB Spiryda","year":"2003","unstructured":"Spiryda LB, Laufer MR, Soiffer RJ, Antin JA (2003) Graft-versus-host disease of the vulva and\/or vagina: diagnosis and treatment. Biol Blood Marrow Transpl 9(12):760\u2013765. https:\/\/doi.org\/10.1016\/j.bbmt.2003.08.001","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"6090_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.htct.2018.06.005","volume":"41","author":"AMN Machado","year":"2019","unstructured":"Machado AMN, Hamerschlak N, Rodrigues M, Piccinato CA, Podgaec S, Mauad LMQ (2019) Female genital tract chronic graft-versus-host disease: a narrative review. Hematol Transfus Cell Ther 41(1):69\u201375. https:\/\/doi.org\/10.1016\/j.htct.2018.06.005","journal-title":"Hematol Transfus Cell Ther"},{"issue":"5","key":"6090_CR81","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3390\/jcm11051196","volume":"11","author":"T Alsuliman","year":"2022","unstructured":"Alsuliman T, Jondreville L, Baylet C, Dann MP, De Bentzmann N, Fontoura ML, Genty C, Huynh A, Ibled D, Yakoub-Agha I, Mercier L, Poirot C, Porcheron S, Tourette-Turgis C, Vernant JP, Vexiau-Robert D, Nguyen S (2022) Sexual and emotional health after allogeneic hematopoietic cell transplantation: a comprehensive review and guidelines from the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC). J Clin Med 11(5):1196. https:\/\/doi.org\/10.3390\/jcm11051196","journal-title":"J Clin Med"},{"issue":"35","key":"6090_CR82","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","volume":"26","author":"P Armand","year":"2008","unstructured":"Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH (2008) Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 26(35):5767\u20135774. https:\/\/doi.org\/10.1200\/JCO.2008.17.7279","journal-title":"J Clin Oncol"},{"issue":"1","key":"6090_CR83","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bjh.13931","volume":"173","author":"P Armand","year":"2016","unstructured":"Armand P, Kim HT, Sainvil MM, Lange PB, Giardino AA, Bachanova V, Devine SM, Waller EK, Jagirdar N, Herrera AF, Cutler C, Ho VT, Koreth J, Alyea EP, McAfee SL, Soiffer RJ, Chen YB, Antin JH (2016) The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol 173(1):96\u2013104. https:\/\/doi.org\/10.1111\/bjh.13931","journal-title":"Br J Haematol"},{"issue":"8","key":"6090_CR84","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","volume":"6","author":"BM Sandmaier","year":"2019","unstructured":"Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R (2019) Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol 6(8):e409\u2013e418. https:\/\/doi.org\/10.1016\/S2352-3026(19)30088-2","journal-title":"Lancet Haematol"},{"issue":"2","key":"6090_CR85","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood.2019003125","volume":"135","author":"J Pidala","year":"2020","unstructured":"Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bola\u00f1os-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML (2020) Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood 135(2):97\u2013107. https:\/\/doi.org\/10.1182\/blood.2019003125","journal-title":"Blood"},{"issue":"11","key":"6090_CR86","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3324\/haematol.2018.195123","volume":"103","author":"PA Carpenter","year":"2018","unstructured":"Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bola\u00f1os-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O\u2019Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, Horowitz MM, Arora M (2018) A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/ sirolimus\/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica 103(11):1915\u20131924. https:\/\/doi.org\/10.3324\/haematol.2018.195123","journal-title":"Haematologica"},{"issue":"9","key":"6090_CR87","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3760\/cma.j.issn.0253-2727.2020.09.003","volume":"41","author":"W Zhu","year":"2020","unstructured":"Zhu W, Feng YM, Chen T, Yao H, Quan Y, Rao J, Gao L, Zhang C, Liu Y, Gao L, Kong PY, Zhang X (2020) [The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant\/steroid-dependent extensive cGVHD]. Zhonghua Xue Ye Xue Za Zhi 41(9):716\u2013722. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2020.09.003","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"10","key":"6090_CR88","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/cid\/cix621","volume":"65","author":"K Tanimura","year":"2017","unstructured":"Tanimura K, Tairaku S, Morioka I, Ozaki K, Nagamata S, Morizane M, Deguchi M, Ebina Y, Minematsu T, Yamada H (2017) Universal screening with use of immunoglobulin G avidity for congenital cytomegalovirus infection. Clin Infect Dis 65(10):1652\u20131658. https:\/\/doi.org\/10.1093\/cid\/cix621","journal-title":"Clin Infect Dis"},{"key":"6090_CR89","doi-asserted-by":"publisher","first-page":"104518","DOI":"10.1016\/j.jcv.2020.104518","volume":"129","author":"PG Maltezou","year":"2020","unstructured":"Maltezou PG, Kourlaba G, Kourkouni \u0395, Luck S, Bl\u00e1zquez-Gamero D, Ville Y, Lilleri D, Dimopoulou D, Karalexi M, Papaevangelou V (2020) Maternal type of CMV infection and sequelae in infants with congenital CMV: systematic review and meta-analysis. J Clin Virol 129:104518. https:\/\/doi.org\/10.1016\/j.jcv.2020.104518","journal-title":"J Clin Virol"},{"issue":"1","key":"6090_CR90","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/TP.0b013e318276a1ef","volume":"95","author":"SH Havenith","year":"2013","unstructured":"Havenith SH, Yong SL, van Donselaar-van KA, van Lier RA, ten Berge IJ, Bemelman FJ (2013) Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8\u2009+\u2009T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation 95(1):184\u2013191 -2664. https:\/\/doi.org\/10.1097\/TP.0b013e318276a1ef","journal-title":"Transplantation"},{"issue":"2","key":"6090_CR91","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/tid.12007","volume":"15","author":"J Kobashigawa","year":"2013","unstructured":"Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L (2013) Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis 15(2):150\u2013162. https:\/\/doi.org\/10.1111\/tid.12007","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"6090_CR92","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1111\/ajt.13327","volume":"15","author":"H Tedesco-Silva","year":"2015","unstructured":"Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J (2015) Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving Everolimus and reduced Tacrolimus doses. Am J Transpl 15(10):2655\u20132664. https:\/\/doi.org\/10.1111\/ajt.13327","journal-title":"Am J Transpl"},{"key":"6090_CR93","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2014.10.016","volume":"113","author":"M Ritt\u00e0","year":"2015","unstructured":"Ritt\u00e0 M, Costa C, Solidoro P, Sidoti F, Libertucci D, Boffini M, Rinaldi M, Baldi S, Cavallo R (2015) Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection. Antiviral Res 113:19\u201326. https:\/\/doi.org\/10.1016\/j.antiviral.2014.10.016","journal-title":"Antiviral Res"},{"key":"6090_CR94","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jcv.2015.04.017","volume":"68","author":"E Durante-Mangoni","year":"2015","unstructured":"Durante-Mangoni E, Andini R, Pinto D, Iossa D, Molaro R, Agrusta F, Casillo R, Grimaldi M, Utili R (2015) Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: a single centre, prospective cohort study. J Clin Virol 68:37\u201342. https:\/\/doi.org\/10.1016\/j.jcv.2015.04.017","journal-title":"J Clin Virol"},{"issue":"21","key":"6090_CR95","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood.V120.21.2740.2740","volume":"120","author":"PB Johnston","year":"2012","unstructured":"Johnston PB, Pinter-Brown L, Rogerio J, Warsi G, Chau Q, Ramchandren R (2012) Everolimus for relapsed\/refractory classical hodgkin lymphoma: Multicenter, open-label, single-arm, phase 2 study. Blood 120(21):2740. https:\/\/doi.org\/10.1182\/blood.V120.21.2740.2740","journal-title":"Blood"},{"key":"6090_CR96","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.8508","author":"F Janku","year":"2014","unstructured":"Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Velez Bravo VM, Hong DS, Westin JR, Nunez C, Fayad L, Neelapu SS (2014) Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. Lymphoma Plasma Cell Disorders. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.8508","journal-title":"Lymphoma Plasma Cell Disorders"},{"issue":"8","key":"6090_CR97","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00277-020-04159-3","volume":"99","author":"B Tessoulin","year":"2020","unstructured":"Tessoulin B, Bouabdallah K, Burroni B, Lamy T, Gressin R, Cartron G, Thieblemont C, Sarkozy C, Haioun C, Casasnovas O, Joubert C, Gyan E, Hermine O, Le Gouill S (2020) Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA. Ann Hematol 99(8):1771\u20131778. https:\/\/doi.org\/10.1007\/s00277-020-04159-3","journal-title":"Ann Hematol"},{"issue":"31","key":"6090_CR98","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","volume":"28","author":"SM Smith","year":"2010","unstructured":"Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B (2010) Temsirolimus has activity in non-mantle cell non-hodgkin\u2019s lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 28(31):4740\u20134746. https:\/\/doi.org\/10.1200\/JCO.2010.29.2813","journal-title":"J Clin Oncol"},{"issue":"21","key":"6090_CR99","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1158\/1078-0432.CCR-09-0842","volume":"15","author":"AE Perl","year":"2009","unstructured":"Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM (2009) A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 15(21):6732\u20136739. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0842","journal-title":"Clin Cancer Res"},{"issue":"12","key":"6090_CR100","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-14-2888","volume":"21","author":"N Daver","year":"2015","unstructured":"Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O\u2019Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M (2015) A phase I\/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed\/refractory acute lymphoblastic leukemia. Clin Cancer Res 21(12):2704\u20132714. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2888","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6090_CR101","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10637-018-0585-x","volume":"36","author":"MT Kasner","year":"2018","unstructured":"Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O\u2019Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36(4):657\u2013666. https:\/\/doi.org\/10.1007\/s10637-018-0585-x","journal-title":"Invest New Drugs"},{"issue":"5","key":"6090_CR102","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10815-019-01439-4","volume":"36","author":"K Wald","year":"2019","unstructured":"Wald K, Cakmak H, Noel M (2019) mTOR inhibitor sirolimus negatively impacts in vitro fertilization outcomes. J Assist Reprod Genet 36(5):947\u2013950. https:\/\/doi.org\/10.1007\/s10815-019-01439-4","journal-title":"J Assist Reprod Genet"},{"issue":"2","key":"6090_CR103","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","volume":"43","author":"GI Kirchner","year":"2004","unstructured":"Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43(2):83\u201395. https:\/\/doi.org\/10.2165\/00003088-200443020-00002","journal-title":"Clin Pharmacokinet"},{"issue":"19","key":"6090_CR104","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.18632\/aging.102355","volume":"11","author":"MV Blagosklonny","year":"2019","unstructured":"Blagosklonny MV (2019) Rapamycin for longevity: opinion article. Aging 11(19):8048\u20138067. https:\/\/doi.org\/10.18632\/aging.102355","journal-title":"Aging"},{"issue":"2","key":"6090_CR105","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/S2666-7568(23)00258-1","volume":"5","author":"DJW Lee","year":"2024","unstructured":"Lee DJW, Hodzic Kuerec A, Maier AB (2024) Targeting ageing with rapamycin and its derivatives in humans: a systematic review. Lancet Healthy Longev 5(2):e152\u2013e162. https:\/\/doi.org\/10.1016\/S2666-7568(23)00258-1","journal-title":"Lancet Healthy Longev"},{"issue":"8","key":"6090_CR106","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1007\/s00520-013-1826-3","volume":"21","author":"ME Peterson","year":"2013","unstructured":"Peterson ME (2013) Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 21(8):2341\u20132349. https:\/\/doi.org\/10.1007\/s00520-013-1826-3","journal-title":"Support Care Cancer"},{"issue":"16","key":"6090_CR107","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630\u20132637. https:\/\/doi.org\/10.1200\/JCO.2008.18.8391","journal-title":"J Clin Oncol"},{"issue":"10","key":"6090_CR108","doi-asserted-by":"publisher","first-page":"e0186235","DOI":"10.1371\/journal.pone.0186235","volume":"12","author":"S Sparagana","year":"2017","unstructured":"Sparagana S, Franz DN, Krueger DA, Bissler JJ, Berkowitz N, Burock K, Kingswood JC (2017) Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. PLoS ONE 12(10):e0186235. https:\/\/doi.org\/10.1371\/journal.pone.0186235","journal-title":"PLoS ONE"},{"issue":"9","key":"6090_CR109","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2298\/vsp1309848i","volume":"70","author":"L Ignjatovi\u0107","year":"2013","unstructured":"Ignjatovi\u0107 L, Hrvacevi\u0107 R, Jovanovi\u0107 D, Kovacevi\u0107 Z, Vavi\u0107 N, Rabrenovi\u0107 V, Tomi\u0107 A, Aleksi\u0107 P, Draskovi\u0107-Pavlovi\u0107 B, Duji\u0107 A, Karan Z, Maksi\u0107 D (2013) Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003\u20132011. Vojnosanit Pregl 70(9):848\u2013853. https:\/\/doi.org\/10.2298\/vsp1309848i","journal-title":"Vojnosanit Pregl"},{"issue":"3","key":"6090_CR110","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1089\/jwh.2017.6451","volume":"27","author":"F Bachmann","year":"2018","unstructured":"Bachmann F, Glander P, Budde K, Bachmann C (2018) High incidence of ovarian cysts in women receiving mTOR inhibitors after renal transplantation. J Womens Health (Larchmt) 27(3):394\u2013398. https:\/\/doi.org\/10.1089\/jwh.2017.6451","journal-title":"J Womens Health (Larchmt)"},{"issue":"8","key":"6090_CR111","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1586\/1744666X.2013.824243","volume":"9","author":"M Framarino-dei-Malatesta","year":"2013","unstructured":"Framarino-dei-Malatesta M, Derme M, Manzia TM, Iaria G, De Luca L, Fazzolari L, Napoli A, Berloco P, Patel T, Orlando G, Tisone G (2013) Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature. Expert Rev Clin Immunol 9(8):781\u2013789. https:\/\/doi.org\/10.1586\/1744666X.2013.824243","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"6090_CR112","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/pediatric15010020","volume":"15","author":"JC Will","year":"2023","unstructured":"Will JC, Siedentopf N, Schmid O, Gruber TM, Henrich W, Hertzberg C, Weschke B (2023) Successful prenatal treatment of cardiac rhabdomyoma in a fetus with tuberous sclerosis. Pediatr Rep 15(1):245\u2013253. https:\/\/doi.org\/10.3390\/pediatric15010020","journal-title":"Pediatr Rep"},{"key":"6090_CR113","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jama.2017.9938","volume":"318","author":"A Bergeron","year":"2017","unstructured":"Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay JO, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker LM, Maillard N, Risso K, Berceanu A, Blaise D, de La Peffault R, Chien JW, Coiteux V, Soci\u00e9 G, ALLOZITHRO Study Investigators (2017) Effect of azithromycin on Airflow decline-Free Survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO Randomized Clinical Trial. JAMA 318:557\u2013566. https:\/\/doi.org\/10.1001\/jama.2017.9938","journal-title":"JAMA"},{"key":"6090_CR114","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1182\/blood.2022016926","volume":"140","author":"N Vallet","year":"2022","unstructured":"Vallet N, Le Grand S, Bondeelle L, Hoareau B, Corneau A, Bouteiller D, Tournier S, Derivry L, Bohineust A, Tourret M, Gibert D, Mayeur E, Itzykson R, Pacchiardi K, Ingram B, Cassonnet S, Lepage P, de Peffault R, Soci\u00e9 G, Bergeron A, Michonneau D (2022) Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation. Blood 140:2500\u20132513. https:\/\/doi.org\/10.1182\/blood.2022016926","journal-title":"Blood"},{"key":"6090_CR115","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0300-483x(02)00612-1","volume":"185","author":"T Vial","year":"2003","unstructured":"Vial T, Descotes J (2003) Immunosuppressive drugs and cancer. Toxicology 185:229\u2013240. https:\/\/doi.org\/10.1016\/s0300-483x(02)00612-1","journal-title":"Toxicology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06090-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06090-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:13:23Z","timestamp":1735866803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06090-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":115,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6090"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06090-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}